We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Method Identifies Fat Malabsorption

By LabMedica International staff writers
Posted on 10 Sep 2014
Print article
Agilent Technologies\' Series 1200 high pressure liquid chromatography (HPLC) system
The Series 1200 high pressure liquid chromatography (HPLC) system (Photo courtesy of AGILENT)
A novel clinical test known as the Serum Retinyl Palmitate Test (RP) has been assessed and validated for the diagnosis of fat malabsorption, and compared to the fecal fat test (FFT).

The differential diagnosis for malabsorptive diarrhea is broad, encompassing luminal, mucosal and lymphatic disorders involving different organ systems and the possibility of undiagnosed systemic endocrine or immunodeficient diseases also highlights the importance of a thorough work-up.

Clinical biochemists at the University of Calgary (AB, Canada) carried out a case-control study on patients identified with chronic diarrhea, defined as persistent symptoms for greater than four weeks, and suspected malabsorption. Healthy control subjects were also recruited. Blood samples were collected at intervals after the administration of oil-soluble vitamin A. A fecal fat test was conducted on samples of patients after the consumption of 100 grams of a fat diet. Patients were defined as malabsorbers if the 72-hour stool fat excretion was greater than 5.9 g/day.

Serum levels of retinol (vitamin A) and RP were measured by reversed-phase high pressure liquid chromatography (HPLC; Waters; Milford, MA, USA). The detection limit for retinol was 0.18 mg/L and for retinyl-palmitate, it was 0.02 mg/L. Sixteen patients completed this study, 8 cases and 8 control subjects. Fecal fat results were available for 15/16 patients. The sensitivity of the FFT was 100%, but the FFT specificity was 42%, as 4/7 control patients were identified as malabsorbers. Cases with short bowel syndrome (SBS) had the lowest RP levels, but this did not meet statistical significance. There was no significant difference for serum RP levels when comparing cases and control patients.

The authors concluded that the RP test did identify patients with severe malabsorption secondary to SBS, but the performance of the RP test in patients with malabsorption from non-SBS etiologies was poor. However, the so-called gold standard, 72-hour FFT, had poor performance characteristics, highlighting the need for more useful diagnostics in identifying malabsorption. The study was published on August 8, 2014, in the journal Clinica Chimica Acta.

Related Links:

University of Calgary 
Waters 


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche)

Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes

The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics